The FDA’s fourth BE approach! [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2015-09-22 16:08 (3920 d 09:08 ago) – Posting: # 15447
Views: 19,468

Dear Helmut, dear all,

Interesting. Seems another Mighty Oracle that went into labour and delivered a mouse.

❝ How could one estimate the sample size? Yet another method for the wish-list of PowerTOST?


Your wish is my command!
Should not that hard to modify power.NTIDFDA() to not shrinken the acceptance range. But in the mean time I suffer from names :cool: for the functions in PowerTOST.
How should we baptize the new baby? Or better having an additional argument in the already mature power.NTIDFDA()? If yes, how to name this?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
125 visitors (0 registered, 125 guests [including 12 identified bots]).
Forum time: 01:16 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5